Long-Term Tolerability And Safety Data Of Abilify(R) In Combination Treatment For Patients With Bipolar I Disorder

ABILIFY® (aripiprazole), when used in combination with lithium or valproate, is a generally well-tolerated long-term treatment for patients with Bipolar I Disorder, who are partially non-responsive to lithium or valproate monotherapy.1 The data presented today at the annual congress for the World Psychiatric Association (WPA) report a favourable long-term safety profile for ABILIFY in combination with lithium or valproate.

More: continued here

Filed under: Bipolar on April 6th, 2009